Dr. Gainor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Nicolls Rd
Boston, MA 11794Phone+1 617-726-2862
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Harvard Medical SchoolClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ponatinib in Advanced NSCLC w/ RET Translocations Start of enrollment: 2013 Sep 01
- Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Start of enrollment: 2015 Oct 01
- Pembrolizumab in Refractory Advanced Esophageal Cancer Start of enrollment: 2017 Jan 18
- Join now to see all
Publications & Presentations
PubMed
- 15 citationsLong-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.H Borghaei, T-E Ciuleanu, J-S Lee, A Pluzanski, R Bernabe Caro
Annals of Oncology. 2023-02-01 - 74 citationsSafety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.F Griesinger, G Curigliano, M Thomas, V Subbiah, C S Baik
Annals of Oncology. 2022-11-01 - 12 citationsTumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.Sara E Schad, Andrew Chow, Levi Mangarin, Heng Pan, Jiajia Zhang
The Journal of Experimental Medicine. 2022-06-06
Journal Articles
- Differential Expression of PD-L1 and IDO1 in Association with the Immune Microenvironment in Resected Lung AdenocarcinomasM Lisa Zhang, Justin F Gainor, Meghan J Mooradian, Nature
- Oxford University Press Has Registered This DOI Pre-PublicationR S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
Abstracts/Posters
- A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin LymphomaJustin Gainor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSC...2019 ASCO Annual Meeting - 6/1/2019
- Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. Immunotherapy for Oncogen...2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Press Mentions
Practical Considerations for Adjuvant vs. Neoadjuvant Immunotherapy in NSCLCJanuary 5th, 2020
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerJune 10th, 2019
Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLCJune 4th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
